***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Patients with chalazia were r and omly allocated to treatment by intralesional triamcinolone injection or incision and curettage . Incision and curettage result ed in a significantly higher rate of resolution by two weeks after treatment OBJECTIVE The research ers sought to assess whether the widely used 1994 Cochrane Highly Sensitive Search Strategy ( HSSS ) for r and omized controlled trials ( RCTs ) in MEDLINE could be improved in terms of sensitivity , precision , or parsimony . METHODS A gold st and ard of 1,347 RCT records and a comparison group of 2,400 non-trials were r and omly selected from MEDLINE .  Terms occurring in at least 1 % of RCT records were identified . Fifty percent of the RCT and comparison group records were r and omly selected , and the ability of the terms to discriminate RCTs from non-trial records was determined using logistic regression . The best performing combinations of terms were tested on the remaining records and in MEDLINE . RESULTS The best discriminating term was " Clinical Trial " ( Publication Type ) . In years where the Cochrane assessment of MEDLINE records had taken place , the strategies identified few additional unindexed records of trials . In years where Cochrane assessment has yet to take place , " R and omized Controlled Trial " ( Publication Type ) proved highly sensitive and precise . Adding six more search terms identified further , unindexed trials at reasonable levels of precision and with sensitivity almost equal to the Cochrane HSSS . CONCLUSIONS Most reports of RCTs in MEDLINE can now be identified easily using " R and omized Controlled Trial " ( Publication Type ) . More sensitive search es can be achieved by a brief strategy , the Centre for Review s and Dissemination/Cochrane Highly Sensitive Search Strategy ( 2005 revision ) We evaluated the safety and efficacy of tobramycin and gentamicin sulfate ophthalmic solutions in the treatment of patients with bacterial infections of the conjunctivas . In this double-masked study involving 66 patients , the two aminoglycosides were found to be equally safe and effective , although the in vitro data suggested that tobramycin may be more efficacious against Pseudomonas infections . Staphylococcus aureus and S. epidermidis were the most frequent isolates from the infected eyes ( 59.8 % and 20.6 % , respectively ) The presented pilot study compared the effectiveness of combined antibiotic ophthalmic solution ( neomycin sulfate , polymyxin B sulfate and gramicidin ) with a placebo ( artificial tear ) in the treatment of hordeolum after incision and curettage ( I&C ) . A r and omized , placebo-controlled trial with patients and investigators blinded from the start started from June 2002 to May 2003 . Subjects were patients with untreated hordeolum who subsequently underwent I&C at the Ophthalmology Department . The patients were r and omized into 2 groups : group A for combined antibiotic ophthalmic solution , and group B for artificial tear containing the antibiotic solution base .  Pain score , mass size and duration of cure were recorded before and on the 3rd and 7th day after treatment . The study included 14 patients in each group . Two subjects in group A and three subjects in group B dropped out . There were no statistically significant differences of all outcomes in both groups , even with the intention-to-treat analysis . The conclusion is combined antibiotic ophthalmic solution is not more effective than placebo in the treatment of hordeolum after Background Loteprednol etabonate 0.5 % and tobramycin 0.3 % ophthalmic suspension ( LE/T ) is indicated for steroid-responsive inflammatory ocular conditions where superficial bacterial ocular infection or a risk of bacterial ocular infection exists . LE/T was shown to be safe in healthy volunteers and patients aged 18 years and older with minimal effect on intraocular pressure ( IOP ) .  Objective The aim of the study was to evaluate the safety of LE/T in pediatric subjects by examining data from two clinical studies . Methods Two r and omized , multicenter , double-masked , parallel-group ( one two-arm , the other four-arm ) studies were conducted in subjects aged 0–6 years ( N = 245 ) . One study assessed LE/T compared with vehicle in the management of lid inflammation ( n = 108 ) and the other compared LE/T with loteprednol etabonate ophthalmic suspension 0.5 % ( LE ) , tobramycin ophthalmic solution 0.3 % ( tobramycin ) , and vehicle in the treatment of blepharoconjunctivitis ( n = 137 ) . In the first study , subjects were r and omized to LE/T or vehicle administered four times daily ( qid ) for the first 7 days followed by twice daily ( bid ) for 7 days along with warm compresses bid for the entire 2 weeks . In the second study , subjects were r and omized to LE/T , LE , tobramycin , or vehicle administered qid for 14 days . Treatment-emergent ocular and non-ocular adverse events ( AEs ) and bilateral vision were assessed at all study visits in both studies . In addition , in the lid inflammation study , IOP was assessed at all visits . The primary safety endpoint in both studies was the incidence of treatment-emergent AEs . Results The incidence of LE/T treatment-emergent AEs was low . A total of four ocular AEs were reported for three LE/T-treated subjects in the first study ( conjunctivitis [ two events ] , meibomian gl and dysfunction , and corneal staining ) , and one ocular AE was reported for an LE/T-treated subject in the second study ( eye pain ) . A total of 13 non-ocular AEs were reported for eight LE/T-treated subjects in the two trials . The most prevalent non-ocular AEs were pyrexia ( three events ) and rash ( two events ) . There were no differences in the incidence of specific ocular and non-ocular AEs between the LE/T group and the comparator treatment group . In both studies , there were no clinical ly meaningful reductions in vision at follow-up visits . Mean IOP and IOP changes from baseline , assessed in the lid inflammation study , were not different between LE/T and vehicle treatment groups at any study visits . Conclusion The results of these two clinical trials demonstrate the short-term safety of treatment with topical LE/T in pediatric subjects ( 0–6 years of age ) with lid inflammation or blepharoconjunctivitis We tested an over-the-counter ophthalmic ointment , yellow mercuric oxide 1 % , for safety and efficacy in decreasing  eyelid-margin bacterial-colony counts . Of 150 patients screened for high bacterial levels , 78 were r and omized in double-blind fashion to either yellow mercuric oxide bid ( 41 patients or 53 % ) or a placebo ( 37 patients or 47 % ) . Bacterial-colony counts were determined at outset and at days 4 and 7 of treatment . At the conclusion of treatment on day 7 , 87 % of patients in the mercuric oxide group were successful in decreasing bacterial counts , compared with 59 % of patients treated with placebo ( P = .01 ) . Side effects were no higher in the active group than in the placebo group . We have shown mercuric oxide 1 % to be safe and effective in reducing  eyelid bacterial-colony counts in patients with hordeolum and blepharitis A trial was conducted to compare the efficacy of the treatment of chalazions by injection of triamcinolone acetonide with conventional incision and curettage . Of the 39 injected cases 77 % resolved completely , though 54 % of the injected cases required a second injection . Of the 30 surgically treated cases 90 % resolved , but 27 % required a second operation . Injection of chalazions with a steroid suspension is a convenient and reasonably effective alternative to the st and ard surgical management of this common condition 
    Output:
    
We did not find any evidence for or against the effectiveness of non-surgical interventions  for the treatment of an internal hordeolum .